Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deissler

Showing results (61-70 of 177) with videos related to

Pageof 18
Sort By:
Experimental Eye Research|November 13, 2016
Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cellsHeidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Klinische Monatsblatter Fur Augenheilkunde|May 7, 2014
[Treatment of diabetic macular oedema with the VEGF inhibitors ranibizumab and bevacizumab: conclusions from basic in vitro studies]G E Lang, G K Lang, H L Deissler
Experimental Eye Research|March 18, 2014
Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cellsHeidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Experimental Eye Research|January 17, 2022
Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cellsHeidrun L Deissler, Matus Rehak, Catharina Busch, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|February 10, 2015
Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cellsHeidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Experimental Eye Research|October 21, 2015
Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptorHeidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Clinical Nuclear Medicine|February 28, 2003
A clinical conundrum solved with indium-111 white blood cell scanningScott C Wright, Jerome L Billingsley, Harriet J Deissler
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|July 19, 2017
Inhibition of Single Routes of Intracellular Signaling is Not Sufficient to Neutralize the Biphasic Disturbance of a Retinal Endothelial Cell Barrier Induced by VEGF-A165Heidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|October 28, 2018
Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradationHeidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Klinische Monatsblatter Fur Augenheilkunde|November 14, 2014
[Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins]G E Lang, G K Lang, H L Deissler
Pageof 18

Showing results (61-70 of 177) with videos related to

Sort By:
Pageof 18
Experimental Eye Research|November 13, 2016
Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cellsHeidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Klinische Monatsblatter Fur Augenheilkunde|May 7, 2014
[Treatment of diabetic macular oedema with the VEGF inhibitors ranibizumab and bevacizumab: conclusions from basic in vitro studies]G E Lang, G K Lang, H L Deissler
Experimental Eye Research|March 18, 2014
Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cellsHeidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Experimental Eye Research|January 17, 2022
Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cellsHeidrun L Deissler, Matus Rehak, Catharina Busch, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|February 10, 2015
Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cellsHeidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Experimental Eye Research|October 21, 2015
Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptorHeidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Clinical Nuclear Medicine|February 28, 2003
A clinical conundrum solved with indium-111 white blood cell scanningScott C Wright, Jerome L Billingsley, Harriet J Deissler
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|July 19, 2017
Inhibition of Single Routes of Intracellular Signaling is Not Sufficient to Neutralize the Biphasic Disturbance of a Retinal Endothelial Cell Barrier Induced by VEGF-A165Heidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|October 28, 2018
Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradationHeidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Klinische Monatsblatter Fur Augenheilkunde|November 14, 2014
[Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins]G E Lang, G K Lang, H L Deissler
Pageof 18